欢迎访问《标记免疫分析与临床》官方网站!
检验医学与甲状腺疾病

甲状腺癌不同治疗方法生存时间分析

展开
  • 中南大学湘雅医学院附属肿瘤医院核医学科,湖南 长沙 410000

收稿日期: 2013-11-19

  修回日期: 2014-01-10

  网络出版日期: 2014-02-24

Analysis on Survival Time of the Thyroid Cancers for the Different Treatment Methods

Expand
  • Department of Nuclear Medicine, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha 410000, China

Received date: 2013-11-19

  Revised date: 2014-01-10

  Online published: 2014-02-24

摘要

目的 分析甲状腺癌患者不同治疗方法的生存时间及影响因素,以期为甲状腺癌治疗提供依据及建议。方法 采用随访研究分析1992年1月至2005年12月收治的分化型甲状腺癌患者的生存资料,对其年龄、性别、婚姻状况、医疗保障方式、职业、文化程度、生育等情况进行统计分析。结果 生存时间单因素分析结果显示,综合治疗组(119.4月) 与单纯治疗组(109.7月)患者的平均生存时间差异有统计学意义(t=2.138, P=0.033);同时生存时间在不同临床分期、不同职业、不同文化程度、不同医保情况之间差异也有统计学意义(P<0.05);但尚未发现不同婚姻状况、不同性别之间的生存时间差异有统计学意义(P>0.05)。结论 手术+131I+TSH抑制治疗的综合治疗组患者平均生存时间大于手术+TSH抑制治疗的单纯治疗组患者平均生存时间,尤其在第Ⅳ期患者中两组中位生存时间的差异更显著;临床分期、职业、文化程度、医保情况对患者的生存时间也有影响。

本文引用格式

石 峰,柴文文 . 甲状腺癌不同治疗方法生存时间分析[J]. 标记免疫分析与临床, 2014 , 21(1) : 63 -67 . DOI: 10.11748/bjmy.issn.1006-1703.2014.01.020

Abstract

Objective To analyze the effects of different treatment methods on survival time of patients with thyroid cancer in order to provide the basis and recommendations for the treatment of thyroid cancer. Methods A follow-up study was conducted to analyze the survival data of patients with differentiated thyroid cancers from January 1992 to December 2005. The study information included patients’ features, such as age, gender, employment status, medical insurance and marriage status. Results Univariate survival analysis showed that the survival time of the combined therapy group and the simple treatment group was statistically significant (P<0.05); survival time in different clinical stages, different occupations, different degree of education, and different health insurance was statistically significant (P<0.05). There was not statistically different between marital status, gender and survival time (P>0.05). Conclusion The average survival time of patients with surgery, 131I and TSH suppression therapy is greater than that with the surgery combined and TSH inhibited therapy, especially in the stage Ⅳ patients. Clinical stage, occupation, education, health care are the determinants for the survival time.
文章导航

/